Literature DB >> 17402722

Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

Andrew Morrell1, Michael S Placzek, Jamin D Steffen, Smitha Antony, Keli Agama, Yves Pommier, Mark Cushman.   

Abstract

Indenoisoquinolines with lactam substituents such as ethylamino, propylamino, and butylamino have previously demonstrated potent biological activity, but an optimal length has never been established. In the present study, a series of simplified indenoisoquinoline analogues possessing a linker spacing of 0-12 carbon atoms between the lactam nitrogen and the terminal amino group have been prepared, determining that 2-4-atom lengths are optimal for topoisomerase I inhibition and cytotoxicity. Using these lengths, analogues were prepared with the amino group and portions of the linker replaced by a pyridine ring. A three-carbon spacer within the pyridine series still demonstrated potent topoisomerase I inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17402722      PMCID: PMC2519145          DOI: 10.1021/jm0613119

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

Review 1.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.

Authors:  Muthusamy Jayaraman; Brian M Fox; Melinda Hollingshead; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

4.  Synthesis and biological activity of some antitumor benzophenanthridinium salts.

Authors:  F R Stermitz; J P Gillespie; L G Amoros; R Romero; T A Stermitz; K A Larson; S Earl; J E Ogg
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

5.  Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Brian C Fort; Marintha Rae Meckley; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

6.  Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.

Authors:  Muthukaman Nagarajan; Xiangshu Xiao; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2003-12-18       Impact factor: 7.446

7.  Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors.

Authors:  Xiangshu Xiao; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2004-10-01       Impact factor: 3.641

8.  Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.

Authors:  Brian M Fox; Xiangshu Xiao; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Bart L Staker; Lance Stewart; Mark Cushman
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

9.  Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

10.  Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.

Authors:  Smitha Antony; Muthusamy Jayaraman; Gary Laco; Glenda Kohlhagen; Kurt W Kohn; Mark Cushman; Yves Pommier
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  19 in total

1.  Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.

Authors:  Trung Xuan Nguyen; Andrew Morrell; Martin Conda-Sheridan; Christophe Marchand; Keli Agama; Alun Bermingham; Alun Bermingam; Andrew G Stephen; Adel Chergui; Alena Naumova; Robert Fisher; Barry R O'Keefe; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-04-26       Impact factor: 7.446

2.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

3.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

4.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

5.  7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Sean DeGuire; Andrew Morrell; Keli Agama; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-08-08       Impact factor: 7.446

6.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

7.  Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.

Authors:  Trung Xuan Nguyen; Monica Abdelmalak; Christophe Marchand; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-03-26       Impact factor: 7.446

8.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

9.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

10.  Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).

Authors:  Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.